View this email in your browser


The following studies are open for patient enrollment by the University of Illinois Cancer Center Clinical Trials Office.

For more information or questions about a study, please email or call

We look forward to serving your patients.

Robert A. Winn, MD
Director, University of Illinois Cancer Center
Associate Vice Chancellor for Community Based Practice
John H. Stewart, IV, MD, MBA
Associate Director for Clinical Sciences
Physician Executive, Oncology Service Line
Browse our list of enrolling clinical trials here




UI Cancer Center Investigator Initiated Clinical Trials
Below are unique UI Cancer Center clinical trials designed by our faculty which are currently enrolling patients (click on the study title for more info):

Hematological Malignancies
A Phase II Study of Intensity Modulated Total Marrow Irradiation (TMI) in Addition to Fludarabine/ Busulfan Conditioning for Allogeneic Transplantation in High Risk AML and Myelodysplastic Syndromes (BMT-05)
PI:  Damiano Rondelli, MD

Lung Cancer
Phase II Study of Anti-PD-1 Antibody Pembrolizumab and Imprime PGG for Patients with Non-small Cell Lung Cancer Who Progressed after First Line Chemotherapy
PI:  Lawrence Feldman, MD

Solid Tumors
Phase I Study of PAC-1 in the Treatment of Advanced Hematologic Malignancy or Solid Tumors (STM-03)
PI:  Oana Danciu, MD
UI Cancer Center Clinical Trial Highlights
A Phase I Study of Safety and Tolerability of Acetazolamide With Temozolomide in Adults with Newly Diagnosed MGMT Promoter Methylated Malignant Glioma (Brain Up)
PI: Kelly Nicholas, MD
Hematological Malignancies
An Open-Label, Phase 2a/2b Study of KRT-232 in Subjects With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post-ET-MF) Who Have Failed a JAK Inhibitor (KRT-232-101)

A Two-Part, Randomized, Open-label, Multicenter, Phase 2a/2b Study of the Efficacy, Safety, and Pharmacokinetics of KRT-232 Compared to Ruxolitinib in Patients with Phlebotomy-Dependent Polycythemia Vera (KRT-232-101)

Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician's Choice of Treatment in Patients with Myelodysplastic Syndrome After Failure of a Hypomethylating Agent (OncoNova 04-30)
PI:  Irum Khan, MD
Phase I Drug-Drug Interaction (DDI) Study with Encorafenib and Binimetinib in Patients with BRAF V600E-Mutant Melanoma or Other Advanced Solid Tumors with the BRAF V600E-Mutation
PI: Rozina Chowdhery, MD

The University of Illinois Cancer Center is comprised of physicians and cancer researchers dedicated to pursuing health equity; working with the community in developing research and treatment options; and studying cancer disparities. We are part of the University of Illinois at Chicago and University of Illinois Hospital and Health Sciences System.

Contact us to find out more information or refer a patient.
Copyright © University of Illinois Cancer Center, All rights reserved.

Our mailing address is:
818 S Wolcott Ave. Chicago, IL 60612

Want to change how you receive these emails?
You unsubscribe from this list.